

101540359  
CASE PA74-32832A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV524615550US  
Express Mail Label NumberJune 23, 2005  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

23 JUN 2005

IN RE PCT NATIONAL STAGE APPLICATION OF

ALTMANN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/14741

FILED: 22 DECEMBER 2003

U.S. APPLICATION NO: Not Yet Assigned

35 USC §371 DATE:

FOR: DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2-AMINO-PHENYL  
METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID  
HORMONE**MS: Amendment**Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/14741, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7859  
Date: June 23, 2005  
\_\_\_\_\_  
Susan Hess  
Attorney for Applicants  
Reg. No. 37,350

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

 10-5-0359  
 APPLICATION NO.  
 Not Yet Assigned  
 APPLICANT  
 ALTMANN ET AL.  
 FILING DATE  
 Herewith

Group

JC20 Rec'd PCT/PTO 23 JUN 2005

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,387,223	6/7/83	Yamamoto Michihiro et al.			
	AB	3,812,257	5/21/74	Inaha et al.			
	AC	5,773,663	6/30/98	Rehnig et al.			
	AD	5,856,503	1/5/99	Maerki et al.			
	AE	3,925,548	12/9/75	Pleffingen			
	AF	6,211,244	4/3/01	Delmar et al.			
	AG						
	AH	ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./					
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	CH 612 186	7/13/79	Swiss			<input type="checkbox"/>	<input type="checkbox"/>
	AN	GB 1 353 789	5/22/74	Great Britain			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 02/24683	3/28/02	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 02/102782	12/27/02	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./						<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/T.N./	AR	Russell et al., "Synthesis and Renal Vasodilator Activity of Substituted 4-alkyl(aryl)-2-oxoquinazolin-1-ylalkanoic Acids", European Journal of Medicinal Chemistry, Vol. 27, No. 3, pp. 277-284, (1992).
/T.N./	AS	Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio: XP002935850 & Miyagishi et al., "General Pharmaceutical Studies on Ciproquazone (SL-573) and its Metabolites" OYL YAKURI, vol. 18, No. 1, pp. 9-22 (1979).
/T.N./	AT	Masai, et al., "Carbon-13 Nuclear Magnetic Resonance Studies of Anti-Inflammatory 2(1H)-Quinazolinones", Chemical & Pharmaceutical Bulletin, Vol. 25, No. 11, pp. 3018-3022, (1977).

EXAMINER	/Tamthom Truong/	DATE CONSIDERED	06/10/2008
----------	------------------	-----------------	------------

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. BOOK  
PAGE 3033A  
APPLICATION NO.  
Not Yet Assigned  
APPLICANT  
ALTMANN ET AL.  
FILING DATE  
HerewithSheet 1 of 1  
10/5/90 359

Group

JC20 Rec'd PCT/PTO 23 JUN 2005

EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio: XP002280289 retrieved from STN accession no. 503745 rn: 37554-38-4 & Mardente et al, "GLC-ECD Determination of 1-(2-Hydroxyethyl)-3-Hydroxy-7-Chloro-1,3-Dihydro-5-(0-Fluorophenyl)-2H-1,4-Benzodiazepin-2-one (SAS 643) in Plasma and Urine and Identification of its main Biotransformation Products" Therapeutic Drug Monitoring, Vol. 3, No. 4, pp. 351-356 (1981)
DB	Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio: XP002280290 retrieved from STN accession no. 1142 database accession no. 1994:244939 rn: 154374-68-2P; 154374-67-1 & M. I. Jaeda at al, "Synthesis of Some Novel 2(1H)-Quinazolinones and 2-Thioxoanalogues from Newly Synthesized 1-acyl-3-alkoxyphenylureas and Tioureas", Journal of Chemical Technology and Biotechnology, Vol. 58, No. 4, pp. 391-394, (1993)
DC	Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio: XP002280291 retrieved from STN accession no. 1277 database accession no. 1981:461773 rn 78350-38-6 & JP 55 143959 (Shionogi and Co.) 1980
DD	Database Crossfire Beilstein 'Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, XP002280292 Database Accession no. 6810088 & Berger et al., ACTA Crystallogr. Sect. C: Cryst. Struct. Commun, Vol. 50, pp. 773-775, (1994)
DE	
DF	
DG	
DH	
DI	
DJ	
DK	
DL	
DM	
DN	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant